The Association for Accessible Medicines (AAM) said it welcomed Congressional efforts to cap blocking patents for biosimilars.

The organization praised the Affordable Prescriptions for Patients Act introduced by Sens. John Cornyn (R-Texas) and Richard Blumenthal (D-Conn.), which advanced to the Senate floor. The legislation goes after gaming tactics like patent thickets designed to stall drug competition.

“AAM believes that capping the total number of biologic patents that can be litigated at a reasonable number would help biosimilar developers enter the market and bring price competition to patients more quickly,” the association said.